Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jose Mattos

Otolaryngology Charlottesville, VA Medical Doctor

NPI 1508151887 CMS profile 1974969

415 Ray C. Hunt Dr Ste 2200, Charlottesville, VA 22903

Open in the dashboard

General payments

$23,769

27 records reported · program years 2019–2024

Research payments

$750

Paid to them · 2 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jose Mattos of Charlottesville, VA is reported in the CMS Open Payments database as having received $23,769 across 27 general payments and $750 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $192 3
2023 General $97 2
2022 General $484 4
2022 Research $750 2
2021 General $15,626 6
2019 General $7,368 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jose Mattos
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Jose Mattos were reported at $0. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Jose Mattos Otolaryngology median Middle half National median
2019 $7,368 $194 $82–$512 $163
2020 $0 $118 $42–$280 $114
2021 $15,626 $167 $63–$444 $132
2022 $484 $216 $84–$545 $149
2023 $97 $235 $93–$588 $160
2024 $192 $280 $111–$699 $164
2025 $0 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $11,966 4 payments
  2. Genzyme Corporation $7,354 11 payments
  3. Regeneron Pharmaceuticals, Inc. $3,660 2 payments
  4. Aerin Medical Inc. $443 2 payments
  5. KARL STORZ Endoscopy-America $175 5 payments
  6. Integra LifeSciences Corporation $156 2 payments
  7. Sanofi-Aventis U.S. LLC $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $20,516 5 payments
  2. Travel and Lodging $2,394 6 payments
  3. Food and Beverage $844 15 payments
  4. Education $14 1 payment
Products named General payments · program years 2019–2024
  1. DUPIXENT Immunology $7,354 11 payments
  2. DUPIXENT Inflammation And Immunology $3,660 2 payments
  3. ACCLARENT AERA $156 2 payments
  4. IMAGE1 X-LINK $77 2 payments
  5. n.a. Ent $59 1 payment
  6. VIVAER STYLUS $36 1 payment
  7. RHINAER STYLUS $36 1 payment
  8. n.a. Ent $17 1 payment
  9. NO PRODUCT DISCUSSED $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Genzyme Corporation $750 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

61

Median for Otolaryngology: 297

Drug cost

$1,065

Median for Otolaryngology: $6,314

Branded share of claims

0%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 23 $597
Ipratropium Bromide Generic 23 $323
Fluticasone Propionate Generic 15 $146

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$90,049

Medicare's payments for the services billed

Medicare patients

255

Average age 73

Services billed

866

132 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 42%
Diabetes 25%
Ischemic heart disease 22%
Depression 19%
Chronic kidney disease 17%
Atrial fibrillation 15%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

29 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record